Are you recommending tocilizumab for any COVID-19 patients?
Current guidelines do not support its use, but the EMPACTA trial suggests it may be effective in a subpopulation of patients.
Answer from: at Community Practice
The utility of IL-6 receptor inhibitors in COVID-19 is controversial, and I do not recommend its routine use in COVID-19 patients at this time. Although early observational studies of IL-6 receptor inhibitors in severe COVID-19 suggested potential benefits, an early RCT of tocilizumab vs. placebo (B...
Comments
at University of Nevada - Las Vegas The REMAP-CAP and EMPACTA trials emphasize that th...
at Northwestern Medical Group I completely agree, and I anticipate there will be...
The REMAP-CAP and EMPACTA trials emphasize that th...
I completely agree, and I anticipate there will be...